AstraZeneca Q3 Profit Jumps 77% to $2.53 Billion Driven by US Expansion and Cancer Drug Sales
AstraZeneca reported a 77% increase in its third-quarter profit, reaching $2.53 billion, fueled by strong US market growth and robust sales of its oncology portfolio. The pharmaceutical giant’s expansion strategies and cancer drug performance underline its strong position in the global pharma sector. AstraZeneca’s Q3 profit surged 77% to $2.53 billion, driven by US expansion…